GlassScriptPhysician profile
Scott Haydel
NPI 1720173719
$14,778.44
in general payments reported to CMS, 2019-2025
64 companies · $2,071 in 2025
The $2,071 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,426 · 2020: $1,787 · 2021: $2,568 · 2022: $2,162 · 2023: $2,174 · 2024: $1,591 · 2025: $2,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,742.29 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,002.95 | 2019-2025 | |
| Pfizer INC. | $1,324.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,167.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,070.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $950.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $684.23 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $605.51 | 2019-2025 | Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.17 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $528.72 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Allergan, INC. | $491.92 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $469.72 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Janssen Pharmaceuticals, INC | $357.91 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $289.03 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $282.26 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $264.52 | 2019-2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Haydel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.